<DOC>
	<DOCNO>NCT02095626</DOCNO>
	<brief_summary>The purpose study investigate effect orally inhale AP-301 primary graft dysfunction lung transplantation .</brief_summary>
	<brief_title>Study Intensive Care Patients Regarding Effect Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Primary Graft Dysfunction</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Being male female recipient AKH ` wait list primary single double LuTX PGD score â‰¥ 1 within 72 hour LuTX Informed consent available History clinically relevant allergy idiosyncrasy AP301 inactive ingredient ( ) investigational product Postoperative ECMO support Paediatric /adolescent recipient ( &lt; 18 year ) Lobar transplantation Retransplantation Combined solid organ transplant Participation drug trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>